We serve Propyl Gallate CAS:121-79-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
|
Specification |
Feed grade |
Pharmaceutical grade |
Food grade |
|
Quality Standard |
Factory |
BP2013 |
FCC-IV |
|
Assay |
98-102% |
≥99.5% |
≥99% |
|
Loss on Drying |
≤0.5% |
≤0.5% |
≤0.5% |
|
Gallic acid |
≤1.0% |
≤0.5% |
≤0.5% |
|
Residue on ignition |
≤0.1% |
≤0.1% |
≤0.1% |
|
APHA |
≤50 |
≤50 |
≤50 |
|
Melting point |
148-150 |
148-150 |
148-150 |
|
Heavy metal |
≤20ppm |
≤10ppm |
≤10ppm |
|
Lead/pb |
5ppm max |
5ppm max |
2ppm max |
|
As |
3ppm max |
3ppm max |
3ppm max |
|
Hg |
1ppm |
1ppm |
1ppm |
Contact us for information like Propyl Gallate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,n-Propyl Gallate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,gallic acid propyl ester Use and application,n-Propyl Gallate technical grade,usp/ep/jp grade.
Related News: Many domestic raw material pharmaceutical and intermediate manufacturing companies with strong capital and talent reserves and advanced technology and processes have developed in the country, and the competitiveness of market participants has continued to increase.3-t-Butoxycarbonylphenylboronic acid manufacturer “Our priority is not only to protect and inform the residents of Boston but also to help this man continue to recover.(1R,3S,4R,5R)-4,6,6-trimethylbicyclo[3.1.1]heptane-3,4-diol supplier The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.4-fluoro-3-methylpyridine vendor The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.The travel restrictions will take effect on Tuesday, Prime Minister Chung Sye-kyun said, as the number of people testing positive for the coronavirus in South Korea increased to 15.
